A phase 2 trial of WX390 in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.
A Study of WX390 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06117540 by Shanghai Jiatan Pharmatech Co., Ltd, with 70 participants planned, started 2021-05-11 and due to reach its primary completion in 2025-06-12. Interventions recorded: WX390.
Shares Shanghai Jiatan Pharmatech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.